{"generic":"Corticotropin","drugs":["Corticotropin","H.P. Acthar"],"mono":{"0":{"id":"142605-s-0","title":"Generic Names","mono":"Corticotropin"},"1":{"id":"142605-s-1","title":"Dosing and Indications","sub":{"0":{"id":"142605-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Collagen disease:<\/b> 40 to 80 units IM or SUBQ every 24 to 72 hours; after prolonged treatment, dose tapering and interval extension may be necessary to avoid adrenal insufficiency<\/li><li><b>Disorder of eye:<\/b> 40 to 80 units IM or SUBQ every 24 to 72 hours; after prolonged treatment, dose tapering and interval extension may be necessary to avoid adrenal insufficiency<\/li><li><b>Disorder of skin:<\/b> 40 to 80 units IM or SUBQ every 24 to 72 hours; after prolonged treatment, dose tapering and interval extension may be necessary to avoid adrenal insufficiency<\/li><li><b>Exacerbation of multiple sclerosis (Acute):<\/b> 80 to 120 units\/day IM or SUBQ for 2 to 3 weeks; after prolonged treatment, dose tapering and interval extension may be necessary to avoid adrenal insufficiency<\/li><li><b>Gout:<\/b> 25 to 40 international units SUBQ and repeat as indicated<\/li><li><b>Inflammatory disorder of musculoskeletal system, Short-term administration during acute exacerbations; Adjunct:<\/b> 40 to 80 units IM or SUBQ every 24 to 72 hours; after prolonged treatment, dose tapering and interval extension may be necessary to avoid adrenal insufficiency<\/li><li><b>Nephrotic syndrome:<\/b> 40 to 80 units IM or SUBQ every 24 to 72 hours; after prolonged treatment, dose tapering and interval extension may be necessary to avoid adrenal insufficiency<\/li><li><b>Sarcoidosis:<\/b> 40 to 80 units IM or SUBQ every 24 to 72 hours; after prolonged treatment, dose tapering and interval extension may be necessary to avoid adrenal insufficiency<\/li><li><b>Transfusion reaction due to serum protein reaction:<\/b> 40 to 80 units IM or SUBQ every 24 to 72 hours; after prolonged treatment, dose tapering and interval extension may be necessary to avoid adrenal insufficiency<\/li><\/ul>"},"1":{"id":"142605-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Collagen disease:<\/b> (greater than 2 years of age) 40 to 80 units IM or SUBQ every 24 to 72 hours; after prolonged treatment, dose tapering and interval extension may be necessary to avoid adrenal insufficiency<\/li><li><b>Disorder of eye:<\/b> (greater than 2 years of age) 40 to 80 units IM or SUBQ every 24 to 72 hours; after prolonged treatment, dose tapering and interval extension may be necessary to avoid adrenal insufficiency<\/li><li><b>Disorder of skin:<\/b> (greater than 2 years of age) 40 to 80 units IM or SUBQ every 24 to 72 hours; after prolonged treatment, dose tapering and interval extension may be necessary to avoid adrenal insufficiency<\/li><li><b>Inflammatory disorder of musculoskeletal system, Short-term administration during acute exacerbations; Adjunct:<\/b> (greater than 2 years of age) 40 to 80 units IM or SUBQ every 24 to 72 hours; after prolonged treatment, dose tapering and interval extension may be necessary to avoid adrenal insufficiency<\/li><li><b>Nephrotic syndrome:<\/b> (greater than 2 years of age) 40 to 80 units IM or SUBQ every 24 to 72 hours; after prolonged treatment, dose tapering and interval extension may be necessary to avoid adrenal insufficiency<\/li><li><b>Sarcoidosis:<\/b> (greater than 2 years of age) 40 to 80 units IM or SUBQ every 24 to 72 hours; after prolonged treatment, dose tapering and interval extension may be necessary to avoid adrenal insufficiency<\/li><li><b>Transfusion reaction due to serum protein reaction:<\/b> (greater than 2 years of age) 40 to 80 units IM or SUBQ every 24 to 72 hours; after prolonged treatment, dose tapering and interval extension may be necessary to avoid adrenal insufficiency<\/li><li><b>West syndrome:<\/b> (less than 2 years of age) 75 units\/m(2) IM twice daily for a 2-week period, followed by a gradual taper over a 2-week period to avoid adrenal insufficiency<\/li><li><b>West syndrome:<\/b> suggested tapering schedule, 30 units\/m(2) IM in the morning for 3 days, followed by 15 units\/m(2) IM in the morning for 3 days, followed by 10 units\/m(2) IM in the morning for 3 days, followed by 10 units\/m(2) IM every other morning for 6 days<\/li><\/ul>"},"3":{"id":"142605-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Collagen disease<\/li><li>Disorder of eye<\/li><li>Disorder of skin<\/li><li>Exacerbation of multiple sclerosis (Acute)<\/li><li>Inflammatory disorder of musculoskeletal system, Short-term administration during acute exacerbations; Adjunct<\/li><li>Nephrotic syndrome<\/li><li>Sarcoidosis<\/li><li>Transfusion reaction due to serum protein reaction<\/li><li>West syndrome<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Adrenal insufficiency; Diagnosis<\/li><li>Gout<\/li><\/ul>"}}},"3":{"id":"142605-s-3","title":"Contraindications\/Warnings","sub":[{"id":"142605-s-3-9","title":"Contraindications","mono":"<ul><li>concomitant use of live or live attenuated vaccines when receiving immunosuppressive corticotropin dose<\/li><li>congenital infection in infants<\/li><li>congestive heart failure<\/li><li>hypertension, uncontrolled<\/li><li>intravenous administration<\/li><li>ocular herpes simplex infection<\/li><li>osteoporosis<\/li><li>peptic ulcers, history or presence of<\/li><li>primary adrenocortical insufficiency  or adrenocortical hyperactivity<\/li><li>scleroderma<\/li><li>sensitivity to porcine protein<\/li><li>surgery, recent<\/li><li>systemic fungal infection<\/li><\/ul>"},{"id":"142605-s-3-10","title":"Precautions","mono":"<ul><li>adrenal insufficiency may occur in adults and infants after discontinuation of prolonged therapy; monitoring recommended; gradual dose reduction may minimize effects<\/li><li>behavioral and mood disturbances may occur; preexisting conditions may be exacerbated<\/li><li>bone density decrease may occur; monitoring for osteoporosis recommended with long-term therapy<\/li><li>cirrhosis; corticotropin effects may be enhanced<\/li><li>congestive heart failure; may cause salt and water retention and elevation of blood pressure<\/li><li>Cushing's syndrome may occur; monitoring recommended, particularly with chronic use<\/li><li>diabetes; may exacerbate condition<\/li><li>gastrointestinal (GI) disorder; GI bleeding, perforation, and gastric ulcers may occur; signs of perforation may be masked; monitoring recommended<\/li><li>hypertension; may cause salt and water retention and elevation of blood pressure; monitoring recommended<\/li><li>hypokalemia may occur; monitoring recommended; potassium supplements may be needed<\/li><li>hypothyroidism; corticotropin effects may be enhanced<\/li><li>immunogenicity potential; may lead to loss of endogenous adrenocorticotropic hormone and drug activity<\/li><li>infection; increased susceptibility to new infection and increased risk of exacerbation, dissemination, or reactivation of latent infections; signs and symptoms of infection may be masked<\/li><li>myasthenia gravis; may exacerbate condition<\/li><li>ophthalmic reactions such as posterior subscapular cataracts, glaucoma with possible optic nerve damage, and secondary ocular infections (due to fungi and viruses) may occur; monitoring recommended<\/li><li>pediatric patients; may reduce growth and physical development; monitoring recommended with long-term therapy<\/li><li>renal insufficiency; may cause salt and water retention and elevation of blood pressure<\/li><li>salt and water retention may occur; monitoring recommended; dietary salt restriction may be necessary<\/li><li>tuberculosis, latent or tuberculin reactivity; may increase risk of reactivation; observe closely and institute chemoprophylaxis if therapy is prolonged<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"142605-s-3-11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>A (AUS)<\/li><\/ul>"},{"id":"142605-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"142605-s-4","title":"Drug Interactions","sub":[{"id":"142605-s-4-13","title":"Contraindicated","mono":"<ul>Rotavirus Vaccine, Live (established)<\/ul>"},{"id":"142605-s-4-14","title":"Major","mono":"<ul><li>Bupropion (theoretical)<\/li><li>Itraconazole (probable)<\/li><\/ul>"},{"id":"142605-s-4-15","title":"Moderate","mono":"<ul><li>Balofloxacin (established)<\/li><li>Besifloxacin (established)<\/li><li>Ciprofloxacin (established)<\/li><li>Enoxacin (established)<\/li><li>Fleroxacin (established)<\/li><li>Flumequine (established)<\/li><li>Gatifloxacin (established)<\/li><li>Gemifloxacin (established)<\/li><li>Levofloxacin (established)<\/li><li>Licorice (probable)<\/li><li>Lomefloxacin (established)<\/li><li>Moxifloxacin (established)<\/li><li>Nadifloxacin (established)<\/li><li>Norfloxacin (established)<\/li><li>Ofloxacin (established)<\/li><li>Pazufloxacin (established)<\/li><li>Pefloxacin (established)<\/li><li>Prulifloxacin (established)<\/li><li>Rufloxacin (established)<\/li><li>Saiboku-To (probable)<\/li><li>Sparfloxacin (established)<\/li><li>Tosufloxacin (established)<\/li><\/ul>"}]},"5":{"id":"142605-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Edema, Hypertension (11% to 19%)<\/li><li><b>Dermatologic:<\/b>Acne (up to 14%)<\/li><li><b>Endocrine metabolic:<\/b>Impaired glucose tolerance, Weight gain (1% to 3%)<\/li><li><b>Gastrointestinal:<\/b>Diarrhea (3% to 14%), Increased appetite (up to 5%)<\/li><li><b>Immunologic:<\/b>Infectious disease (20% to 46%)<\/li><li><b>Psychiatric:<\/b>Altered behavior, Irritability (7% to 19%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Cardiomegaly (up to 3%)<\/li><li><b>Endocrine metabolic:<\/b>Cushing's syndrome (3% to 22%)<\/li><li><b>Neurologic:<\/b>Encephalitis due to human herpes simplex virus, Relapse, Seizure (3% to 12%)<\/li><\/ul>"},"6":{"id":"142605-s-6","title":"Drug Name Info","sub":{"0":{"id":"142605-s-6-17","title":"US Trade Names","mono":"H.P. Acthar<br\/>"},"2":{"id":"142605-s-6-19","title":"Class","mono":"<ul><li>Endocrine-Metabolic Agent<\/li><li>Pituitary Hormone, Anterior<\/li><\/ul>"},"3":{"id":"142605-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"142605-s-7","title":"Mechanism Of Action","mono":"<ul><li>Repository corticotropin is an adrenocorticotropic hormone (ACTH) analogue. Repository and endogenous corticotropin stimulate the adrenal cortex to secrete cortisol, corticosterone, aldosterone, and other weak androgenic substances. Elevated cortisol levels in the plasma suppresses ACTH release. The trophic effects of ACTH and repository corticotropin appear to be mediated by cyclic adenosine monophosphate. Repository corticotropin also binds to melanocortin receptors.<\/li><li>The mechanism of action of corticotropin in the treatment of infantile spasms is unknown.<\/li><\/ul>"},"8":{"id":"142605-s-8","title":"Pharmacokinetics","sub":{"4":{"id":"142605-s-8-27","title":"Elimination Half Life","mono":"IV: 15 min.<br\/>"}}},"9":{"id":"142605-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>do not administer IV; only use IM or SUBQ<br\/><\/li><li><b>Intramuscular<\/b><br\/>warm to room temperature before using; do not over pressurize the vial prior to removing the product<br\/><\/li><li><b>Subcutaneous<\/b><br\/>warm to room temperature before using; do not over pressurize the vial prior to removing the product<br\/><\/li><\/ul>"},"10":{"id":"142605-s-10","title":"Monitoring","mono":"<ul><li>clinical improvement in disease symptoms is indicative of efficacy<\/li><li>sodium and potassium levels<\/li><li>unmasked disease symptoms (such as hyperglycemia, infection, abnormal cardiac function, and body weight changes); during and for a period following discontinuation of therapy<\/li><li>blood pressure; during and for a period following discontinuation of therapy<\/li><li>bone density in all patients and growth and physical development in pediatric patients with prolonged therapy<\/li><li>cataracts, glaucoma, or signs and symptoms of ophthalmic infection with prolonged therapy<\/li><li>signs of adrenal insufficiency (eg, weakness, hyperpigmentation, weight loss, and hypotension) after drug discontinuation, especially following chronic use<\/li><li>signs and symptoms of Cushing's syndrome, especially with chronic use<\/li><li>signs and symptoms of gastrointestinal perforation or bleeding; during and for a period following discontinuation of therapy<\/li><li>signs and symptoms of reactivation of infection in patients with latent tuberculosis or tuberculin reactivity<\/li><\/ul>"},"13":{"id":"142605-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to avoid live vaccines during therapy due to drug-induced immunosuppression.<\/li><li>Drug may cause fluid retention, alteration in glucose tolerance, elevation in blood pressure, behavioral and mood changes, increased appetite, and weight gain.<\/li><li>In infants and children, this drug may also cause irritability and sleep disturbances and Cushing syndrome, skeletal growth inhibition, osteoporosis, and decreased bone density with prolonged use.<\/li><li>Advise patient or caregiver of patient to report any new onset of seizure, an increase in blood pressure, or change in stool color or presence of blood in the stool.<\/li><li>Instruct patient or caregiver of patient to report signs\/symptoms of infection (including fever) or adrenocortical insufficiency (weakness, fatigue, lethargy, anorexia, weight loss, hypotension, abdominal pain, or hyperpigmentation).<\/li><li>With long-term treatment, advise patient against sudden discontinuation of drug.<\/li><\/ul>"}}}